Home Latest Articles
Latest Articles
  • Jianping REN, Xiaohu LIU, Xiuhua GAO, Tianyi WANG
    World Clinical Drug. 2022, 43(11): 1457-1461.
    Objective

    To investigate the effect of Shenqi Bufei method combined with western medicine in the treatment of chronic obstructive pulmonary disease (COPD).

    Methods

    A total of 110 patients with stable lung qi deficiency syndrome of mild to moderate COPD admitted to our hospital from September 2018 to August 2020 were selected, and randomly divided into control group and intervention group with 55 pattents in each group. The control group were treated with conventional western medicine, and the intervention group were treated with Shenqi Bufei method on the basis of the control group. The course of the treatment was 3 months. The curative effect, traditional Chinese medicine syndrome score, pulmonary function index [forced expiratory volume in the first second (FEV1), forced vital capacity (FVC)], blood oxygen index [arterial partial pressure of carbon dioxide (PaCO2), arterial partial pressure of oxygen (PaO2)], 6-minute walking distance (6MWD) and incidence of adverse reactions were compared between the two groups.

    Results

    The total effective rate of intervention group was significantly higher than that of control group (P<0.05). After treatment, FEV1, FVC, PaO2 and 6MWD in the two groups were increased, and the intervention group was significantly higher than that of control group (P<0.05). After treatment, the traditional Chinese medicine syndrome score and PaCO2 of the two groups were decreased, and the intervention group was significantly lower than that of control group (P<0.05). The total incidence of adverse reactions in the intervention group was significantly lower than that of control group (P<0.05).

    Conclusion

    For mild to moderate COPD patients with lung qi deficiency syndrome, Shenqi Bufei method combined with western medicine has an ideal effect, which can significantly reduce the traditional Chinese medicine syndrome score, significantly improve lung function and blood oxygen index, effectively enhance exercise tolerance, and has high drug safety.

  • Xia ZHANG, Zhengzhang LI, Ying XU, Hui LI
    World Clinical Drug. 2022, 43(11): 1462-1469.
    Objective

    To explore the protective effect of sacubitril valsartan combined with metoprolol in treatment of coronary atheroselerotic heart disease (CHD) with chronic heart failure (CHF).

    Methods

    A total of 180 patients with CHD and CHF were randomly divided into intervention group and control group, with 90 cases in each group. The control group were treated with angiotensin-converting enzyme inhibitor or angiotensin Ⅱ receptor antagonist combined with metoprolol, the intervention group were treated with sacubitril valsartan combined with metoprolol for 6 months. Clinical efficacy and major adverse cardiovascular events were compared between two groups. The left ventricular ejection fraction (LVEF), maximum early filling speed/maximum filling speed in late diastole (E/A), left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD) and left ventricular mass index (LVMI) were measured before and after treatment. The plasma N-terminal brain natriuretic peptide (NT-proBNP), serum cardiac troponin Ⅰ(cTn Ⅰ), creatine kinase isoenzyme (CK-MB), serum creatinine (Scr), cystatin C (CysC) and potassium were determined. The Minnesota living with heart failure questionnaire (MLHFQ) score, Lee's heart failure score and 6 min walking test (6MWT) were measured.

    Results

    Total effective rate of intervention group was significantly higher than that of control group (P<0.05). After treatment, there was no significant difference in blood pressure and heart rate between two groups (P>0.05), but the LVEF and E/A of intervention group were higher than those of control group, and LVEDD, LVESD, and LVMI were significantly lower than those of control group (P<0.05). After treatment, the levels of NT-proBNP, cTnⅠ, CK-MB and CysC in intervention group were significantly lower than those of control group (P<0.05), but there was no significant difference in Scr and potassium between two groups (P>0.05). After treatment, the 6MWT of intervention group was significantly higher than that of control group, while the MLHFQ and Lee's heart failure scores were significantly lower than those of control group (P<0.05). The follow-up results showed that the readmission rate for heart failure of intervention group were significantly lower than that of control group (P<0.05). The 2-year follow-up results showed that incidence of major adverse cardiovascular events (MACE) of intervention group were significantly lower than that of control group (P<0.05).

    Conclusion

    Sacubitril valsartan combined with metoprolol can improve the heart and kidney function of patients with CHD and CHF, inhibit left ventricular remodeling, improve exercise endurance and quality of life, and reduce the rate of MACE.

  • Jing ZHOU, Lixiao TIAN, Lina ZHANG
    World Clinical Drug. 2022, 43(11): 1470-1474.
    Objective

    To analyze the effects of Xingnaojing injection combined with nalmefene hydrochloride on oxidative stress response and neurotransmitter levels in patients with acute severe alcoholism.

    Methods

    A total of 73 patients with acute severe alcoholism in the department of emergency of Henan provincial people's hospital from February 2020 to March 2021 were selected and divided into observation group (n=38) and control group (n=35) according to the lottery method. The control group was treated with nalmefene hydrochloride, and the observation group was treated with Xingnaojing injection combined with nalmefene hydrochloride. The clinical efficacy, symptom relief time, waking time, and oxidative stress response [serum β-endorphin (β-EP), malondialdehyde (MDA), superoxide dismutase (SOD)] and neurotransmitter levels [dopamine (DA), norepinephrine (NE), and 5-hydroxytryptamin (5-HT)] were compared between the two groups.

    Results

    After treatment, the total effective rate of observation group was 92.11%, which was significantly higher than 68.57% of control group (P<0.05). The symptom relief time and waking time of the observation group were shorter than those of the control group [(6.38±0.62) vs (8.35±0.81) h, (1.01±0.23) vs (1.37±0.52) h](P<0.05). The levels of β-EP and MDA in the observation group were lower than those in the control group [(208.96±16.87) vs (237.98±15.86) ng/L, (6.08±1.32) vs (8.73±1.50) nmol/L](P<0.05). The SOD was higher than that in the control group [(85.37±11.32) vs (67.58±10.02) kU/L](P<0.05). The levels of DA, NE and 5-HT in the observation group were lower than those in the control group [(125.30±12.98) vs (146.23±15.36) ng/L, (232.56±19.02) vs (290.38±12.85) ng/ml, (130.75±12.60) vs (161.28±11.07) ng/L](P<0.05).

    Conclusion

    Xingnaojing injection combined with nalmefene hydrochloride can effectively improve the clinical symptoms of patients with acute severe alcoholism, regulate oxidative stress reaction and neurotransmitter level, and help patients recover, which can be further promoted in clinical practice.

  • Mingjun RUI, Xiwen DU, Li XIE, Haijun CAO, Jian YIN
    World Clinical Drug. 2022, 43(11): 1475-1485.
    Objective

    This study aims to evaluate the cost-utility of dimethyl fumarate (DMF) compared with teriflunomide (TFM) for relapsing multiple sclerosis (RMS) in China.

    Method

    A Markov model was constructed based on a from healthcare system perspective in China over a 37-year horizon. Drug acquisition costs, monitoring costs, disease management costs, disease relapse costs and adverse events management costs were included. QALYs was used as the outcome. Utility of different model statuses and disutility caused by adverse events were also considered in the inputs. Costs and utility inputs were derived from published studies, public documents, and expert interviews. One-way sensitivity analysis (DSA) and probability sensitivity analysis (PSA) were conducted to evaluate the robustness of the results.

    Results

    Over a 37-year time horizon, DMF led to an incremental QALY gain of 0.16 (4.10 of DMF and vs 3.94 of TFM) and reduced the total cost of ¥128,923 yuan (¥513,105 of DMF and vs ¥642,028 of TFM) compared with TFM. Cost savings are mainly drug acquisition costs, monitoring costs, disease management costs, disease relapse costs and adverse events management costs. DSA results showed that the disability progression hazard ratio values of TFM and DMF were the main drivers. PSA results showed a 100% probability of DMF being cost-effective compared to TFM at a threshold of 1 GDP per capita.

    Conclusion

    DMF dominates the TFM for the treatment of RMS from healthcare system perspective in China.

  • Yuan DING, Bingyan CAO, Xi MENG, Chunxiu GONG
    World Clinical Drug. 2022, 43(11): 1486-1491.
  • Yu ZHANG, Qiaoling YANG, Wenjuan HU
    World Clinical Drug. 2022, 43(11): 1492-1495.
  • Xiaojie LIN, Zelin YU, Hongbo FU, Xiajiong LUO, Xiaobing HONG
    World Clinical Drug. 2022, 43(11): 1496-1501.
  • Ruihua CHEN, Xiaoying DING, Li ZHAO, Yufan WANG, Yongde PENG
    World Clinical Drug. 2022, 43(11): 1502-1506.
  • Yijiong TAN, Li ZHAO, Shuangshuang YAO, Fang FANG, Liying ZHU, Fang LIU
    World Clinical Drug. 2022, 43(11): 1507-1510.
  • Tianqi SHEN, Xiangjie LI, Xingxing YIN, Yongming ZHANG
    World Clinical Drug. 2022, 43(11): 1511-1515.

    Remimazolam is a new ultrashort-acting benzodiazepine that acts on the γ-aminobutyric acid receptor. Remimazolam is rapidly hydrolyzed into inactive carboxylic acid metabolite by esterase metabolism, and its metabolism is independent on liver and kidney function. It has a short half-life and is not affected by the infusion time. Long time infusion is not easy to accumulate and can be antagonized by flumazenil, which has less impact on hemodynamics and respiration. These characteristics make remimazolam an ideal sedative drug. In recent years, it has been used in painless diagnosis and treatment, sedation of ICU, and the induction and maintenance of general anesthesia, the prospects of application are board. This paper mainly reviews the mechanism of action, pharmacokinetics, the influence on organ function, and the research progress of clinical application, so as to provide a theoretical basis for its clinical application.

News